On May 26, 2026 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, reported that two abstracts showcasing the Company’s RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held from May 29 to June 2, 2026 in Chicago, IL. The Company’s proprietary RedTail platform is a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will present preclinical data on its lead program, CLD-401. CLD-401 is a systemically delivered virotherapy designed to selectively target tumors and enable high-level expression of IL-15 superagonist ("IL-15 SA"), a known T- and NK-cell activator, driving profound immune changes in the tumor microenvironment ("TME"), including the recruitment and activation of NK, NK-T, and gamma delta (γδ) T-cells that lead to a robust therapeutic response in immunocompetent animal models. The Company expects to file an IND for CLD-401 by the end of 2026.
The Company will also present preclinical data on CLD-501, the lead compound from its in situ T-cell engager ("TCE") approach. CLD-501 is a systemically delivered virotherapy designed to selectively target tumors and simultaneously enable the high-level in situ expression of a TROP-2 TCE and IL-15 SA.
"The data presented at ASCO (Free ASCO Whitepaper) demonstrate the potential for the RedTail platform as systemic virotherapy that can deliver genetic medicine to metastatic sites after systemic administration," said Antonio F. Santidrian, PhD, Chief Scientific Officer of Calidi. "The ability of CLD-401 to induce high levels of IL15-SA expression in the TME may drive activity in patients that have progressed on current IO therapies while the tandem expression of a TCE and a T-cell activator as seen with CLD-501 may overcome the barriers to TCE efficacy in solid tumors."
The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.
(Press release, Calidi Biotherapeutics, MAY 26, 2026, View Source [SID1234666082])